Update shared on15 Aug 2025
With both the discount rate and revenue growth forecasts holding steady, analyst valuation for DarioHealth remained unchanged, with the consensus price target steady at $1.96.
What's in the News
- Shareholders ratified the appointment of Kesselman & Kesselman (PwC) as independent auditor for 2025.
- Stockholders authorized a reverse stock split at a ratio between 2:1 and 25:1, to be implemented by September 15, 2025, at the Board’s discretion.
- Collaboration announced with GreenKey Health to launch a tiered, data-driven care program targeting sleep apnea and related comorbidities, aiming to secure payer contracts and improve health outcomes.
- Four new studies presented at the ADA conference showcased sustained GLP-1 weight loss, strong AI-powered personalization results, and 89% accuracy in predicting blood glucose levels.
- Proposal submitted to increase authorized common shares from 160 million to 400 million.
Valuation Changes
Summary of Valuation Changes for DarioHealth
- The Consensus Analyst Price Target remained effectively unchanged, at $1.96.
- The Discount Rate for DarioHealth remained effectively unchanged, at 11.82%.
- The Consensus Revenue Growth forecasts for DarioHealth remained effectively unchanged, at 18.3% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.